23 results on '"Fazli L"'
Search Results
2. Tumor regression grading after neoadjuvant chemotherapy in bladder cancer: Validation in an independent cohort
3. Targeting enzalutamide-resistant prostate cancer using the novel androgen receptor inhibitor ODM-201
4. Targeting heat-shock protein 27 enhances sensitivity to sorafenib treatment in renal cancer in vitro and in vivo
5. T-DM1, a novel HER2 antibody-cytotoxic drug conjugate, has anti-metastatic potential and is a promising targeted therapy for bladder cancer with HER2 IHC score 2+/3+
6. 209 A phase 1 clinical trial assessing an intravesical administered second-generation antisense oligonucleotide targeting heat shock protein 27 in bladder cancer
7. 929 Targeting lactate transporters for the treatment of urothelial carcinoma
8. 138 Exploring a novel therapeutic target for neuroendocrine prostate cancer using a xenograft model of trans-differentiation
9. 1046 Evaluation of carbonic anhydrase IX as a potential therapeutic target in urothelial carcinoma
10. 791 Notch2-HEY axis promotes tumour growth in bladder cancer through cell cycle progression and de-differentiation
11. 355 - Head-to-head comparison of efficacy of darolutamide (ODM-201) vs. enzalutamide on mutated forms of the androgen receptor
12. 63 Erythropoietin accelerates the regeneration of ureteral function in a murine model of obstructive uropathy
13. 747 - Targeting enzalutamide-resistant prostate cancer using the novel androgen receptor inhibitor ODM-201
14. 390 - Tumor regression grading after neoadjuvant chemotherapy in bladder cancer: Validation in an independent cohort
15. 972 - T-DM1, a novel HER2 antibody-cytotoxic drug conjugate, has anti-metastatic potential and is a promising targeted therapy for bladder cancer with HER2 IHC score 2+/3+
16. 849 - Targeting heat-shock protein 27 enhances sensitivity to sorafenib treatment in renal cancer in vitro and in vivo
17. 802 A role for the hedgehog effector Gli1 in mediating stent-induced ureteral aperistalsis and smooth muscle dysfunction
18. 522 Targeting HER2 with trastuzumab-DM1 (T-DM1) is highly effective in preclinical models of HER2-overexpressing bladder cancer
19. 39 Notch2 promotes bladder cancer progression: Pre-clinical rationale for a novel targeted therapy
20. 516 Targeting IGF-BP2 and 5 with the bispecific antisense oligodeoxynucleotide OGX-225 in chemoresistant bladder cancer
21. 403 Patient-derived primary xenografts in the preclinical development of novel targeted therapies for bladder cancer
22. 235 Clusterin knockdown synergizes activity of second generation anti-androgen, MDV3100, through enhancing AR degradation and repression of FKBP52 in castrate resistant prostate cancer model
23. 236 The combination of carbidopa plus bicalutamide suppresses androgen-receptor transactivation, induces apoptosis and delays castration-resistant prostate cancer progression
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.